Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Priority Review Voucher Sales Prices Level Off In 2017

Nov 27 2017

• By Sue Sutter

Priority Review Voucher

Related Content

BioMarin's Brineura Approval Shows FDA's Open Door For Orphan Drugs

May 02 2017

Priority Review Voucher Expansion Could Be Bad, Program Creator Says

May 13 2016

Related Companies

BioMarin Pharmaceutical Inc.

AbbVie Inc.

United Therapeutics Corporation

Sanofi

ViiV Healthcare

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Rare Diseases Financing Regulation BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window